Effect of rilimogene galvacirepvec/rilimogene glafolivec on intra/peritumoral immune infiltrate in patients with localized prostate cancer undergoing radical prostatectomy.

5083Background: PSA-TRICOM (Prostvac) is a vector-based vaccine designed to generate a robust immune response (IR) against PSA–expressing tumor cells. To date, studies of Prostvac in patients with ...